HELOISA HELENA DE SOUSA MARQUES
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina - Líder
59 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 59
- Hepatitis C in Children and Adolescents of a Brazilian Tertiary Center Identifying Patients Eligible for Direct-Acting Antivirals(2020) HIRSCH, Camila Bellettini; PEREIRA, Maria Fernanda Badue; BENEVIDES, Gabriel Nuncio; BERNARDES, Tamires Miranda; PALANDRI, Giovanna Gavros; BASTOS, Karina Lucio de Medeiros; TOMA, Ricardo Katsuya; AZEVEDO, Ramiro Anthero de; MARQUES, Heloisa Helena de SousaWe evaluated 113 pediatric patients with chronic hepatitis C from 2009 to 2019 at a Brazilian tertiary center. Seventy patients received pegylated-interferon treatment. The sustained virologic response was 61.4%, and 92.8% reported side effects. Currently, we are following 39 patients with chronic hepatitis C, 24 of whom are eligible for treatment with direct-acting antivirals according to Brazilian recommendations.
bookPart Doenças causadas por helmintos(2017) SAKANE, Pedro Takanori; MARQUES, Heloisa Helena de SousabookPart Meningites e meningoencefalites(2023) SANTOS, Ariane Guissi dos; MARQUES, Heloisa Helena de SousabookPart Arboviroses(2023) BUENO, Catarina; CRUZ, Vitória Paula Dias; MARQUES, Heloisa Helena de Sousa; SUMITA, Nairo Massakazu- Mycobacterial Disease in Immunocompromised Children in a High Endemic Area(2018) SCHUWARTZ, Constance Dell' Santo Vieira; GALASTRI, Anne Layze; DURIGON, Giuliana Stravinskas; LITVINOV, Nadia; PEREIRA, Maria Fernanda Badue; MARQUES, Heloisa Helena de Sousa
bookPart Infecções congênitas e perinatais(2017) MARQUES, Heloisa Helena de Sousa; ANDRADE, Samantha Brasil de; NAGAIASSU, Meire; CECCON, Maria Esther Jurfest Rivero; GALASTRI, Anne Layze- Cytomegalovirus infection in transplant recipients(2015) AZEVEDO, Luiz Sergio; PIERROTTI, Ligia Camera; ABDALA, Edson; COSTA, Silvia Figueiredo; STRABELLI, Tania Mara Varejao; CAMPOS, Silvia Vidal; RAMOS, Jessica Fernandes; LATIF, Acram Zahredine Abdul; LITVINOV, Nadia; MALUF, Natalya Zaidan; CAIAFFA FILHO, Helio Hehl; PANNUTI, Claudio Sergio; LOPES, Marta Heloisa; SANTOS, Vera Aparecida dos; LINARDI, Camila da Cruz Gouveia; YASUDA, Maria Aparecida Shikanai; MARQUES, Heloisa Helena de SousaCytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.
bookPart Adenomegalias(2022) LITVINOV, Nadia; MARQUES, Heloisa Helena de SousabookPart Doenças exantemáticas(2022) PEREIRA, Maria Fernanda Bádue; MARQUES, Heloisa Helena de SousabookPart Tuberculose(2022) PAULA, Camila Sanson Yoshino de; MARQUES, Heloisa Helena de Sousa